- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biogen Inc (BIIB)
Track today's live Biogen (BIIB) share price, performance and key data on this page with our current NASDAQ:BIIB stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Biogen share price on the NASDAQ exchange. Use the dropdown to switch exchange for the BIIB share price, head to our technical summary section, which provides analysis on Biogen share price buy/sell indicators using real-time data (or discuss the Biogen (BIIB) stock price today with other investors in the Biogen NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:BIIB share price (ISIN: US09062X1037) to enhance your trading decisions with our free investment tools and resources.
What Is the Biogen Inc Share Price Today?
The Biogen share price today is 248.35.
What Is the Stock Symbol for Biogen Inc
The stock symbol (or 'ticker') for Biogen Idec Inc is "BIIB."
What Stock Exchange Does Biogen Inc Trade On?
Biogen Idec Inc is listed and trades on the NASDAQ stock exchange.
Is Biogen Inc a Good Stock to Buy?
Determining whether Biogen (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:BIIB share price (ISIN: US09062X1037) to enhance your trading decisions with our free investment tools and resources.
What Is the Biogen Inc Share Price Today?
The Biogen share price today is 248.35.
What Is the Stock Symbol for Biogen Inc
The stock symbol (or 'ticker') for Biogen Idec Inc is "BIIB."
What Stock Exchange Does Biogen Inc Trade On?
Biogen Idec Inc is listed and trades on the NASDAQ stock exchange.
Is Biogen Inc a Good Stock to Buy?
Determining whether Biogen (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
240.00
250.03
52 wk Range
153.77
258.78
BIIB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
240.00250.03
52 wk Range
153.77258.78
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BIIB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
264.82
Upside
+6.63%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
Biogen Idec Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
Biogen Idec Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell
Analyst Ratings
25 Buy
10 Hold
1 Sell
Ratings:
36 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 264.82
(+6.63% Upside)
Biogen Inc SWOT Analysis
Neuroscience Pionee | Biogen, a leader in neuroscience and rare diseases, faces challenges in its MS franchise while pursuing growth in Alzheimer's and genetic medicine |
Financial Health | Despite market volatility, Biogen maintains strong profitability with a 76% gross margin and 13% free cash flow yield, signaling resilience |
Pipeline Potential | Explore Biogen's R&D focus on genetic medicine and targeted therapies, with analysts divided on its ability to offset declining MS revenues |
Market Valuation | With price targets ranging from $115 to $206, Biogen's stock appears undervalued at $128.39, presenting potential upside amid strategic initiatives |
Biogen Inc Earnings Call Summary for Q3/2026
- Biogen posted Q3 2026 EPS of $2.62, beating estimates by 30%, with revenue of $2.8B exceeding forecasts by 6% on strong growth portfolio performance.
- Growth products now comprise 63% of core pharma revenue, up 49% YoY; LEQEMBI rose 67%, SPINRAZA 23%, and SYFOVRE 27% as MS franchise stabilizes.
- Company raised FY 2026 non-GAAP EPS guidance to $12.20-$13.00; Apellis acquisition ahead of plan, expected accretive to earnings in 2027.
- CEO Viehbacher highlighted pipeline reset with six new programs including three molecular entities, targeting 20+ early-stage programs ahead.
- Shares rose 1.13% to $255.59, near 52-week high; challenges include 27% rise in operating costs and $6.4B net debt from Apellis acquisition.
Last Updated: 28/10/2026, 13:54
Read Full TranscriptEarnings
Latest Release
28/10/2026
EPS / Forecast
2.62 / 2.02
Revenue / Forecast
2.8B / 2.64B
Compare BIIB to Peers and Sector
Metrics to compare | BIIB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBIIBPeersSector | |
|---|---|---|---|---|
P/E Ratio | 105.6x | 27.3x | −0.2x | |
PEG Ratio | −1.34 | −0.88 | 0.00 | |
Price/Book | 1.9x | 3.5x | 2.6x | |
Price / LTM Sales | 3.6x | 3.0x | 2.8x | |
Upside (Analyst Target) | 6.6% | 13.7% | 65.6% | |
Fair Value Upside | Unlock | 4.7% | 10.0% | Unlock |
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer’s disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Biogen (NASDAQ: BIIB) Share Price Today?
The Biogen stock price today is 248.35 USD.
What Stock Exchange Does Biogen (BIIB) Trade On?
Biogen is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Biogen?
The stock symbol (also called a 'ticker') for Biogen is "BIIB."
What Is the Current Biogen Market Capitalisation?
As of today, Biogen (NASDAQ: BIIB) market cap is 36.06B USD.
What Is Biogen's (BIIB) Earnings Per Share (TTM)?
The Biogen EPS is currently 2.36 (Trailing Twelve Months).
When Is the Next Biogen Earnings Date?
Biogen's next earnings report will be released on 17/02/2027.
Is BIIB a Buy or Sell From a Technical Analyst Perspective?
Based on today's Biogen moving averages and other technical indicators, the daily buy/sell signal for BIIB stock is Buy.
How Many Times Has Biogen Stock Split?
Biogen has split 2 times. (See the BIIB stock split history page for full effective split date and price information.)
How Many Employees Does Biogen Have?
Biogen has 7500 employees, based on their latest Companies House report.
What is the current trading status of Biogen (NASDAQ: BIIB)?
As of 07/11/2026, Biogen (BIIB) is trading at a share price of 248.35 USD, with a previous close of 248.35 USD. The stock has fluctuated within a day range of 240.00 USD to 250.03 USD, while its 52-week range spans from 153.77 USD to 258.78 USD.
What Is Biogen (BIIB) Price Target According to Analysts?
The average 12-month price target for Biogen is 264.82 USD, with a high estimate of 325 USD and a low estimate of 175 USD. 25 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +6.63% Upside potential.
What Is the BIIB Premarket Price?
BIIB's last pre-market stock price is 240.17 USD. The pre-market share volume is 2,320.00, and the stock has decreased by -3.76, or -1.54%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.